Parkinson's drug leukine passes early safety check in small study
NCT ID NCT03790670
First seen Jan 04, 2026 · Last updated May 19, 2026 · Updated 22 times
Summary
This early-phase study tested whether a drug called Leukine (sargramostim) is safe for people with Parkinson's disease when taken for 36 months. Seven participants received a weight-based dose 5 days a week. Researchers monitored side effects, immune system changes, and movement symptoms. The goal was to see if longer treatment is tolerable and to gather data for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.